Spots Global Cancer Trial Database for Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Official Title: A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Study ID: NCT01032070
Study Description
Brief Summary: This is a phase 2 study to evaluate the efficacy of single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma.
Detailed Description: This is a phase 2 study involving a 1:1 randomization of 40 patients with recurrent or refractory pediatric ependymoma who will receive either erlotinib or oral etoposide.
Eligibility
Minimum Age: 1 Year
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama at Birmingham Dept. of Pediatric-Hematology/Oncology, Birmingham, Alabama, United States
Center for Cancer and Blood Disorders-Phoenix Children's Hospital, Phoenix, Arizona, United States
Children's Hospital of Orange County (CHOC), Orange, California, United States
Stanford University and Lucile Packard Children's Hospital, Palo Alto, California, United States
Children's Hospital Center for Cancer and Blood Disorders, Aurora, Colorado, United States
Children's National Medical Center - D.C. Center for Cancer and Blood Disorders, Washington, District of Columbia, United States
University of Miami, Miami, Florida, United States
Emory University Children's Healthcare of Atlanta Aflac Cancer Center & Blood Disorders, Atlanta, Georgia, United States
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Dana-Farber Cancer Institute Department of Pediatric Neuro-oncology, Boston, Massachusetts, United States
Amplatz Children's Hospital University of Minnesota Medical Center- Pediatric Hematology Oncology, Minneapolis, Minnesota, United States
Steven D Hassenfeld Children's Center - New York University, New York, New York, United States
Columbia University Children's Hospital of New York Presbyterian Child & Adolescent Oncology Center, New York, New York, United States
Oregon Health & Sciences University Doembecher Children's Hospital, Portland, Oregon, United States
Penn State Hershey Children's Hospital, Hershey, Pennsylvania, United States
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Children's Medical Center, Dallas Center for Cancer and Blood Disorders, Dallas, Texas, United States
University of Wisconsin Pediatric Hematology/Oncology Department, Madison, Wisconsin, United States
Strollery Children's Hospital Division of Hematology/Oncology, Edmonton, Alberta, Canada
Children's and Women's Health Center of BC Division of Hematology/ Oncology/ BMT, Vancouver, British Columbia, Canada
Hospital for Sick Children, Toronto, Ontario, Canada
Birmingham Children's Hospital, Birmingham, , United Kingdom
Royal Hospital for Sick Children, Glasgow, , United Kingdom
Paediatric Oncology and Haematology Offices, Leeds, , United Kingdom
Alder Hey Children's NHS Foundation Trust Department of Oncology, Liverpool, , United Kingdom
Royal Manchester Children's Hospital Ward 84, Manchester, , United Kingdom
University of Nottingham Children's Brain Tumour Research Centre, Nottingham, , United Kingdom
Royal Marsden Hospital, Sutton, , United Kingdom
Contact Details
Name: Medical Monitor
Affiliation: Astellas Pharma Global Development
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
